Navigation Links
Sinovac Presents at Two Investor Conferences in May 2011
Date:5/9/2011

BEIJING, May 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to present at two upcoming investor conferences in New York City.

  • Piper Jaffray 8th Annual China Growth Conference
  • Sinovac is scheduled to present at 4:00 pm on Tuesday, May 17, 2011 and will be participating in one-on-one meetings

  • A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com .

  • Oppenheimer 5th Annual China Dragon Conference
  • Sinovac is scheduled to present at 8:30 am ET on Wednesday, May 18, 2011 and will be participating in one-on-one meetings on May 18

  • About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

    Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel:  +86-10-8279-9871/9659Fax:  +86-10-6296-6910Email: ir@sinovac.comInvestors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel:  +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.comMediaJason RandoThe Ruth GroupTel:  +1-646-536-7025Email:  jrando@theruthgroup.com
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
    2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
    3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
    4. Sinovac Announces Plan to Launch Offering of Common Shares
    5. Sinovac Announces Recent Developments
    6. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
    7. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
    8. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
    9. Sinovac Files Shelf Registration Statement
    10. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
    11. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/24/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... USD 330.6 million by 2021 from USD 275.9 ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... industries, increasing spending on pharmaceutical R&D, and growth ... factors driving the market growth for particle counters. ...
    (Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
    (Date:2/23/2017)... Calif., Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), ... solutions for the treatment of chronic pain, today reported financial ... 31, 2016. 2016 Accomplishment & Highlights: ... year 2016, an increase of 228% as reported, over the ... 2016, an increase of 612% over the prior year ...
    Breaking Medicine Technology:
    (Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
    (Date:2/24/2017)... ... 24, 2017 , ... Castle Farms, the celebrated Northern ... with the winning couple announced on Feb. 14, 2017, on Facebook. The free ... vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and ...
    (Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
    (Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
    (Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
    Breaking Medicine News(10 mins):